Technically, this would not qualify for a 3wk tight pattern. IBD sets the buy point at 123.47. However, IBD also has an advanced buying strategy buy point based on the break of the downward trend line of the left side of the base. The last 3 weeks have had tight closes after they have broken this trend line as they are less than 1% apart. Now seems to be a safe time to step in and wait for lift off.
I like the fundamentals of this company the best out of all the big biotech names. It looks like it's calming down here finally after having been sold off hard with all the other biotech / med companies, and now has consolidated and held above the orange downtrend lines. It keeps putting in higher lows on the weekly chart. This looks like a good place to enter here.
Initial entry will be the break of the 3 wk tight pattern at 111.50
Add at 114.00 as it breaks the double bottom peak .
Add as it breaks to new highs at 123.47 IBD buy point.
It holds a 91 composite rating on IBD, weak A/D rating of D+, everything else looks good on the company.
IBD STOCK CHECKUP®
Enter Stock Symbol/Company
GET STOCK CHECKUP
Gilead Sciences Inc (GILD)
ABOUT GILD: DEVELOPS THERAPEUTICS TO TREAT VIRAL, FUNGAL, RESPIRATORY AND CARDIOVASCULAR DISEASES.
D+.
Composite Rating 91
MARKET DIRECTION AND INDUSTRY GROUP FOR GILD
General Market
Market in confirmed uptrend
Industry Group
Industry Group Rank (1 to 197) 47
FUNDAMENTAL PERFORMANCE FOR GILD
Current Earnings
EPS Due Date 02/01/2016
EPS Rating 97
EPS % Chg (Last Qtr) 75%
Last 3 Qtrs Avg EPS Growth 69%
# Qtrs of EPS Acceleration 1
EPS Est % Chg (Current Qtr) 21%
Estimate Revisions
Last Quarter % Earnings Surprise 12.2%
Annual Earnings
3 Yr EPS Growth Rate 106%
Consecutive Yrs of Annual EPS Growth 4
EPS Est % Chg for Current Year 51%
Sales, Margin, ROE
SMR Rating A
Sales % Chg (Last Qtr) 37%
3 Yr Sales Growth Rate 60%
Annual Pre-Tax Margin 65.0%
Annual ROE 99.4%
Debt/Equity Ratio 77%
TECHNICAL PERFORMANCE FOR GILD
Price And Volume
Price $108.40
RS Rating 71
% Off 52 Week High -12%
Price vs. 50-Day Moving Average 4%
50-Day Average Volume 11.8 Mil
Supply And Demand
Market Capitalization $159.3 B
Accumulation/Distribution Rating D+
Up/Down Volume 1.4
% Change In Funds Owning Stock 2%
Qtrs Of Increasing Fund Ownership 8
I like the fundamentals of this company the best out of all the big biotech names. It looks like it's calming down here finally after having been sold off hard with all the other biotech / med companies, and now has consolidated and held above the orange downtrend lines. It keeps putting in higher lows on the weekly chart. This looks like a good place to enter here.
Initial entry will be the break of the 3 wk tight pattern at 111.50
Add at 114.00 as it breaks the double bottom peak .
Add as it breaks to new highs at 123.47 IBD buy point.
It holds a 91 composite rating on IBD, weak A/D rating of D+, everything else looks good on the company.
IBD STOCK CHECKUP®
Enter Stock Symbol/Company
GET STOCK CHECKUP
Gilead Sciences Inc (GILD)
ABOUT GILD: DEVELOPS THERAPEUTICS TO TREAT VIRAL, FUNGAL, RESPIRATORY AND CARDIOVASCULAR DISEASES.
D+.
Composite Rating 91
MARKET DIRECTION AND INDUSTRY GROUP FOR GILD
General Market
Market in confirmed uptrend
Industry Group
Industry Group Rank (1 to 197) 47
FUNDAMENTAL PERFORMANCE FOR GILD
Current Earnings
EPS Due Date 02/01/2016
EPS Rating 97
EPS % Chg (Last Qtr) 75%
Last 3 Qtrs Avg EPS Growth 69%
# Qtrs of EPS Acceleration 1
EPS Est % Chg (Current Qtr) 21%
Estimate Revisions
Last Quarter % Earnings Surprise 12.2%
Annual Earnings
3 Yr EPS Growth Rate 106%
Consecutive Yrs of Annual EPS Growth 4
EPS Est % Chg for Current Year 51%
Sales, Margin, ROE
SMR Rating A
Sales % Chg (Last Qtr) 37%
3 Yr Sales Growth Rate 60%
Annual Pre-Tax Margin 65.0%
Annual ROE 99.4%
Debt/Equity Ratio 77%
TECHNICAL PERFORMANCE FOR GILD
Price And Volume
Price $108.40
RS Rating 71
% Off 52 Week High -12%
Price vs. 50-Day Moving Average 4%
50-Day Average Volume 11.8 Mil
Supply And Demand
Market Capitalization $159.3 B
Accumulation/Distribution Rating D+
Up/Down Volume 1.4
% Change In Funds Owning Stock 2%
Qtrs Of Increasing Fund Ownership 8